Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257838 | 0.73 | — | — | |
| SCHEMBL449836 | 0.71 | — | — | |
| SCHEMBL954349 | 0.69 | — | — | |
| SCHEMBL29031998 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL29032005 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL30577822 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL28455177 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL3304004 | 0.63 | IDO1 (0.41) | CA12CA1CA9 | |
| SCHEMBL1256668 | 0.63 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL504770 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1343503-B1 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7309704-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1747182-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | Acadia Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060030588-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION | 2006-02-09 | — | — | US | disclosed |
| US-6982267-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005108337-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | ACADIA PHARMACEUTICALS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-6946476-B2 | For therapy of metabolic and eating disorders such as obesity and hyperphagia, diabetes | SCHERING CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1343503-A4 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20040006086-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-01-08 | — | — | US | disclosed |
| EP-1343503-A1 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030055062-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION | 2003-03-20 | — | — | US | disclosed |
| WO-2002049648-A1 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055062-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | CA12 4675/4885CA1 4481/4885CA9 2960/4885 |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | GPER1, ESR1, ESR2 | CA12 4235/4885CA1 4532/4885CA9 2735/4885 |
| US-20040006086-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | CA12 4675/4885CA1 4481/4885CA9 2960/4885 |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | CA12 3314/4885CA1 3770/4885CA9 2036/4885 |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ESR2, GPER1, ESRRG | CA12 4379/4885CA1 3986/4885CA9 3354/4885 |
| US-20060030588-A1 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | CA12 4647/4885CA1 4552/4885CA9 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.